Ionut Bebu1, Barbara H Braffett2, Trevor J Orchard3, Gayle M Lorenzi4, David M Nathan5, William H Herman6, John M Lachin2. 1. The Biostatistics Center, The George Washington University, Rockville, MD, United States. Electronic address: ibebu@bsc.gwu.edu. 2. The Biostatistics Center, The George Washington University, Rockville, MD, United States. 3. University of Pittsburgh, Pittsburgh, PA, United States. 4. University of California, San Diego, CA, United States. 5. Massachusetts General Hospital, Harvard Medical School, Boston, MA, United States. 6. University of Michigan, Ann Arbor, MI, United States.
Abstract
AIMS: We assessed whether and to what extent established cardiovascular disease (CVD) risk factors moderate (enhance/reduce) the effect of hyperglycemia on CVD outcomes in the long-term follow-up of the Diabetes Control and Complications Trial type 1 diabetes (T1D) cohort (N = 1441). METHODS: Moderation of the effect of glycemia on subsequent risk of major adverse cardiovascular events (MACE: fatal or non-fatal myocardial infarction or stroke) and any-CVD (MACE plus confirmed angina, silent MI, revascularization, or congestive heart failure) was assessed separately using interaction terms between HbA1c and other risk factors in Cox proportional hazards models. RESULTS: Over a median follow-up of 29 years, there were 120 MACE cases and 239 any-CVD cases. Higher pulse, higher triglycerides, use of calcium channel blockers, and presence of neuropathy individually enhanced (p < 0.01) the effect of glycemia on any-CVD. Higher pulse and triglyceride levels, albumin excretion rate, hypertension, and no family history of type 2 diabetes enhanced (p < 0.01) the effect of glycemia on MACE. CONCLUSIONS: Such moderation analyses identify subgroups with increased CVD risk who might especially benefit from earlier and/or more intensive glycemic control. Interventions treating modifiable moderating factors may independently reduce the risk of CVD and also reduce the risk associated with a higher HbA1c.
AIMS: We assessed whether and to what extent established cardiovascular disease (CVD) risk factors moderate (enhance/reduce) the effect of hyperglycemia on CVD outcomes in the long-term follow-up of the Diabetes Control and Complications Trial type 1 diabetes (T1D) cohort (N = 1441). METHODS: Moderation of the effect of glycemia on subsequent risk of major adverse cardiovascular events (MACE: fatal or non-fatal myocardial infarction or stroke) and any-CVD (MACE plus confirmed angina, silent MI, revascularization, or congestive heart failure) was assessed separately using interaction terms between HbA1c and other risk factors in Cox proportional hazards models. RESULTS: Over a median follow-up of 29 years, there were 120 MACE cases and 239 any-CVD cases. Higher pulse, higher triglycerides, use of calcium channel blockers, and presence of neuropathy individually enhanced (p < 0.01) the effect of glycemia on any-CVD. Higher pulse and triglyceride levels, albumin excretion rate, hypertension, and no family history of type 2 diabetes enhanced (p < 0.01) the effect of glycemia on MACE. CONCLUSIONS: Such moderation analyses identify subgroups with increased CVD risk who might especially benefit from earlier and/or more intensive glycemic control. Interventions treating modifiable moderating factors may independently reduce the risk of CVD and also reduce the risk associated with a higher HbA1c.
Authors: David M Nathan; Patricia A Cleary; Jye-Yu C Backlund; Saul M Genuth; John M Lachin; Trevor J Orchard; Philip Raskin; Bernard Zinman Journal: N Engl J Med Date: 2005-12-22 Impact factor: 91.245
Authors: Naji Younes; Patricia A Cleary; Michael W Steffes; Ian H de Boer; Mark E Molitch; Brandy N Rutledge; John M Lachin; William Dahms Journal: Clin J Am Soc Nephrol Date: 2010-05-06 Impact factor: 8.237
Authors: Katarina Eeg-Olofsson; Jan Cederholm; Peter M Nilsson; Björn Zethelius; Ann-Marie Svensson; Soffia Gudbjörnsdóttir; Björn Eliasson Journal: Diabetes Care Date: 2010-04-27 Impact factor: 19.112
Authors: Shona J Livingstone; Helen C Looker; Eleanor J Hothersall; Sarah H Wild; Robert S Lindsay; John Chalmers; Stephen Cleland; Graham P Leese; John McKnight; Andrew D Morris; Donald W M Pearson; Norman R Peden; John R Petrie; Sam Philip; Naveed Sattar; Frank Sullivan; Helen M Colhoun Journal: PLoS Med Date: 2012-10-02 Impact factor: 11.069